Rating Change
UBS analysts reiterated a Neutral rating on AbbVie Inc. (NYSE:ABBV) on July 13, 2026.
reiterateNYSE:ABBV
UBS Reiterates Neutral Rating on AbbVie Inc. (ABBV)
Rating Change UBS analysts reiterated a Neutral rating on AbbVie Inc. (NYSE:ABBV) on July 13, 2026. Market Context AbbVie Inc.
Market Context
AbbVie Inc. operates in the Healthcare sector. The stock currently trades at $248.00 with a market capitalization of $410.1B. The stock has gained 13.2% over the past 52 weeks.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for AbbVie Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for AbbVie Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 13, 2026 | UBS | Neutral | N/A |
| Jul 13, 2026 | BMO Capital | Outperform | N/A |
| Jul 10, 2026 | B of A Securities | Buy | N/A |
| Jul 10, 2026 | RBC Capital | Outperform | N/A |
| Jul 10, 2026 | Wells Fargo | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View ABBV Stock Page
Frequently Asked Questions
What does a Neutral rating mean for ABBV?
A Neutral rating from UBS reflects the analyst's outlook on AbbVie Inc. (NYSE:ABBV). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ABBV forecast page.